DTB questions NICE neuropathic pain guidance for pregabalin
17th June 2010
The editorial in the latest Drug and Therapeutics Bulletin (DTB) questions the recommendation in the recent guideline on neuropathic pain from the UK National Institute for health and Clinical Excellence (NICE) that clinicians should offer oral amitriptyline or pregabalin as first-line treatment (see our news 2010-04-20).
DTB extract (full text requires subscription)
NICE neuropathic pain guidance
Recent news
- SMC accepts fentanyl single dose nasal spray
- NICE end of life care commissioning guide
- AWMSG approve tapentadol m/r for restricted use
- US FDA approve fentanyl sublingual spray
- NPSA Rapid Response Report on spinal connectors
- Update: anti-epileptics monograph
- NPC review m/r oxycodone/naloxone
- Prednisolone EC blister packs recalled from Teva
- Citalopram and escitalopram maximum daily doses restricted
- Extemporaneous thalidomide oral suspension stability study
News archive
- 2012
- 2011
- 2010
- 2009
- 2008
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000